The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $58 from $57 and keeps an Overweight rating on the shares. The firm says Dawnzera was approved by the FDA on time with a ...

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

The latest international Bageshri Banerjee news and views from Reuters - one of the world's largest news agencies ...

In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as a prophylactic therapy in the rare and genetic disease hereditary angioedema ...

In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $64 from $63 and keeps a Buy rating on the shares ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

The drug, Dawnzera, is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults ...